Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for Lexeo Therapeutics, Inc. Common Stock (LXEO).
- Disclosed ownership: 4%.
- Date of event: 30 Sep 2025.
BlackRock, Inc. - 30 Sep 2025 SCHEDULE 13G/A Report for Lexeo Therapeutics, Inc. Common Stock (LXEO)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- LXEO
- Shares outstanding
- 54,211,100 shares
- Disclosed Ownership
- 2,168,444 shares
- Ownership
- 4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Oct 2025, 18:13:44 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 04 Feb 2025
- Next filing
- 21 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 4% ownership in Lexeo Therapeutics, Inc. Common Stock (LXEO) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 04 Feb 2025.
- Current filing was accepted on 17 Oct 2025, 18:13.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 4% | 2,168,444 | 2,129,602 | 0 | Spencer Fleming | Managing Director |